Dr. Reddy’s Laboratories informs about press release

08 Dec 2025 Evaluate
Dr. Reddy’s Laboratories has informed that Dr. Reddy’s Laboratories SA, a wholly-owned subsidiary of the company (‘Dr. Reddy’s’) has entered into a strategic collaboration and exclusive Licensing agreement with Immutep SAS, a wholly-owned subsidiary of Immutep (ASX: IMM; NASDAQ: IMMP) (‘Immutep’) to develop and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. The details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed. A press release to be issued in relation to the above matter is enclosed.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Lab Share Price

1279.65 6.70 (0.53%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×